Hip Arthropathy Associated With Other ConditionsNCT06959498
Long-term Survival of THA After Pelvic and/or Femoral Osteotomy
An observational study of Hip Arthropathy Associated With Other Conditions and Hip Dysplasia, run by Central Hospital, Nancy, France.
Trial summary
Analyze the long-term clinical and radiological outcomes of total hip arthroplasty (THA) in patients with hip dysplasia treated by pelvic osteotomy, femoral osteotomy, shelf acetabuloplasty, or a combination of these interventions, performed during childhood or early adulthood. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hip Arthropathy Associated With Other Conditions, Hip Dysplasia, Survival, Prosthesis
- What is being tested?
- Total hip arthroplasty
- Type of treatment
- Surgery or procedure
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2025to 1 Jun 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Male and female patients, with no age limit, operated in the Centre Chirurgical Emile Gallé, Nancy, France, between 1998 and 2010
Who may be able to join
- patients who underwent THA between 1998 and 2010 and had a prior surgical treatment for hip dysplasia (pelvic, femoral osteotomy, shelf acetabuloplasty or combined osteotomy)
Who cannot join
- -
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Oliver Roche contact
About this study
Analyze the long-term clinical and radiological outcomes of total hip arthroplasty (THA) in patients with hip dysplasia treated by pelvic osteotomy, femoral osteotomy, shelf acetabuloplasty, or a combination of these interventions, performed during childhood or early adulthood. The aim is to understand the impact of these early interventions on THA survival and long-term joint function.
- Being tested
- Total hip arthroplasty
- Medical subject headings
- Hip Dislocation, Prosthesis Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Total hip arthroplastyProcedure or surgery
Total hip arthroplasty
| Study group | Role | What they receive |
|---|---|---|
| Pelvic osteotomy or shelf acetabuloplasty | Total hip arthroplasty after pelvic osteotomy or shelf acetabuloplasty Receives: Procedure: Total hip arthroplasty | |
| Femoral osteotomy | Total hip arthroplasty after femoral osteotomy Receives: Procedure: Total hip arthroplasty | |
| Combined osteotomy | Total hip arthroplasty after a combination of pelvic osteotomy or shelf acetabuloplasty, and femoral osteotomy Receives: Procedure: Total hip arthroplasty |
What is being measured
The primary outcome is the main question the study is designed to answer.
survival
Study of 15 year survival of THA
Measured: 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2025
- Study start1 May 2025 (estimated)
- Primary completion15 May 2025 (estimated)
- Study completion1 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip Arthropathy Associated With Other ConditionsStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Olivier ROCHE, Central Hospital, Nancy, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06959498
- Sponsor's protocol ID
- 2024PI083
- Status last verified
- Apr 2025
- First submitted
- 28 Apr 2025
- Last updated
- 6 May 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Survival of THA After Pelvic and/or Femoral Osteotomy
- ClinicalTrials.gov ID
- NCT06959498
- Acronym / sponsor ID
- 2024PI083
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 1 May 2025 (estimated)
- Primary completion
- 15 May 2025 (estimated)
- Study completion
- 1 Jun 2025 (estimated)
- First posted
- 6 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Analyze the long-term clinical and radiological outcomes of total hip arthroplasty (THA) in patients with hip dysplasia treated by pelvic osteotomy, femoral osteotomy, shelf acetabuloplasty, or a combination of these interventions, performed during childhood or early adulthood. The aim is to understand the impact of these early interventions on THA survival and long-term joint function.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Pelvic osteotomy or shelf acetabuloplasty | – | Procedure: Total hip arthroplastyTotal hip arthroplasty after pelvic osteotomy or shelf acetabuloplasty |
| Femoral osteotomy | – | Procedure: Total hip arthroplastyTotal hip arthroplasty after femoral osteotomy |
| Combined osteotomy | – | Procedure: Total hip arthroplastyTotal hip arthroplasty after a combination of pelvic osteotomy or shelf acetabuloplasty, and femoral osteotomy |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Male and female patients, with no age limit, operated in the Centre Chirurgical Emile Gallé, Nancy, France, between 1998 and 2010
Key inclusion criteria (1 listed)
- patients who underwent THA between 1998 and 2010 and had a prior surgical treatment for hip dysplasia (pelvic, femoral osteotomy, shelf acetabuloplasty or combined osteotomy)
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Total hip arthroplastyTotal hip arthroplasty | Procedure or surgery | Combined osteotomy, Femoral osteotomy, Pelvic osteotomy or shelf acetabuloplasty |
Primary outcome
survival
Time frame: 20 years
Study of 15 year survival of THA
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2025.
Related trials for Hip Arthropathy Associated With Other Conditions
RecruitingObservational study
Long-term Aseptic Revision & Advanced Hip Arthroplasty Database
Hip Arthropathy Associated With Other Conditions
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Oliver Roche contact
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Arthropathy Associated With Other Conditions and Hip Dysplasia, run by Central Hospital, Nancy, France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 May 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julia Richard (+33628749343, julia.richard97@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
survival (time frame: 20 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2025.